Why G3139 works poorly in cancer trials but might work well against HIV

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 537-540

  Parris, George E ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CPG OLIGODEOXYNUCLEOTIDE; FAS ANTIGEN; OBLIMERSEN; PHOSPHOROTHIOIC ACID; PROTEIN BCL 2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; PROVIRUS; RETROVIRUS; VIRUS TRANSCRIPTION;

ANIMALS; ANTI-HIV AGENTS; APOPTOSIS; CLINICAL TRIALS; GENES, P53; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES; TREATMENT OUTCOME;

CORONAVIRUS; HEPATITIS B VIRUS; HUMAN HERPESVIRUS 4; HUMAN T-LYMPHOTROPIC VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 34447260521     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.044     Document Type: Article

References (24)

1. Raynaud F.I., Orr R.M., Godard P.M., et al. Pharmacokinetics of G3139, a phosphorothiodate oligodeoxynucleotide antisense to Bcl-2 after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281 (1997) 420-427
2. Bettaieb A., Dubrez-Daloz L., Launay S., et al. Bcl-2 proteins: targets and tools for chemosensitisation of tumor cells. Curr Med Chem Anticancer Agents 3 (2003) 307-318
3. van de Donk N.W., de Weerdt O., Veth G., et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia. 18 (2004) 1078-1084
4. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
5. Lim YP, Lim TT, Chan YL. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene 2006 (September) [Epub ahead of print].
6. Barboza JA. Liu G. Ju Z. El-Naggar AK. Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc Natl Acad Sci USA 2006 (December) [Epub ahead of print].
7. White E. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ 13 (2006) 1371-1377
8. Gabrilovich D.I. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 6 (2006) 823-832
9. Parris G.E. The cell clone ecology hypothesis and the cell fusion model of cancer progression and metastasis: history and experimental support. Med Hypotheses 66 (2006) 76-83
10. Crescenzi E., Palumbo G., and Brady H.J. Bcl-2 activates a programme of premature senescence in human carcinoma cells. Biochem J 375 (2003) 263-274
11. Cheng N., Janumyan Y.M., Didion L., Van Hofwegen C., Yang E., and Knudson C.M. Bcl-2 inhibition of T-cell proliferation is related to prolonged T-cell survival. Oncogene. 23 (2004) 3770-3780
12. Li W.Q., Jiang Q., Aleem E., Kaldis P., Khaled A.R., and Durum S.K. IL-7 promotes T cell proliferation through destabilization of p27Kip1. J Exp Med 203 (2006) 573-582
13. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 20 (2002) 709-760
14. Del Bello B., Valentini M.A., Zunino F., Comporti M., and Maellaro E. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene. 20 (2001) 4591-4595
15. Murphy M.F., Metcalfe P., Waters A.H., et al. Incidence and mechanism of neutropenia and thrombocytopenia in patients with human immunodeficiency virus infection. Br J Haematol 66 (1987) 337-340
16. Rossi G., Gorla R., Stellini R., et al. Prevelenve, clinical, and laboratory features of thrombocytopenia among HIV-infected individuals. Aids Res Hum Retroviruses 6 (1990) 261-269
17. Siliciano R. HARRT for life. Hopkins HIV Rev 11 (1999) 2
18. Bahbouhi B., Landay A., and Al-Harthi L. Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood. 103 (2004) 4581-4587
19. Arnoult D., Petit F., Lelievre J.D., et al. Caspase-dependent and -independent T-cell death pathways in pathogenic simian immunodeficiency virus infection: relationship to disease progression. Cell Death Differ 10 (2003) 1240-1252
20. Parris G.E. Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites. Med Hypotheses 62 (2004) 354-357
21. Parris G.E. AIDS: caused by development of resistance to drugs in a non-target intracellular parasite. Med Hypotheses 68 (2007) 151-157
22. Lacy J., Loomis R., Grill S., Srimatkandada P., Carbone R., and Cheng Y.C. Systemic Bcl-2 antisense oligodeoxynucleotide in combination with cisplatin cures EBV+ nasopharyngeal carcinoma xenografts in SCID mice. Int J Cancer 119 (2006) 309-316
23. Chugh P. Fan S. Planelles V. Maggirwar SB. Dewherst S. Kim B. Infection of human immunodeficiency viruses and intercellular Tat protein exert a pro-survival effect in a human microglial cell line. J Mol Biol 2006 (November) [Epub ahead of print].
24. Pauls E., Senserrich J., Clotet B., and Este J.A. Inhibition of HIV-1 replication by RNA interference of p53 expression. J Leukoc Biol 80 (2006) 659-667